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Abstract
We have explored MICA/B expression and its relationship with innate inflammatory infiltrate in renal cell carcinoma
(RCC). The expression of MICA/B, CD16, CD56, and CD68 in 140 RCC lesions contained in a tissue microarray (TMA)
was investigated by immunohistochemistry. MICA/B gene and protein expressions in Caki-1 cells were analyzed by reverse
transcription–polymerase chain reaction and flow cytometry, respectively. Natural killer (NK) cells were studied by flow
cytometry. All the RCC lesions (n = 140) were MICA/B–positive. MICA/B was mainly expressed in the cytoplasm of tumor
cells, whereas stromal cells were negative. Renal cell carcinoma lesions showed low NK cell infiltration, although they were
rich in CD16+CD56− cells, strongly resembling macrophages. CD16+ macrophage infiltration was more frequently detect-
able in metastatic lesions compared with primary tumors (P = .0223) and was associated with poor RCC differentiation
(P = .007). To investigate mechanisms potentially underlying the lack of NK cells infiltration into MICA/B–positive RCC
lesions, we used Caki-1 RCC cells. Caki-1 expressed MICA and MICB genes. However, MICA protein was not detectable
in Caki-1 cells, whereas MICB protein was detectable in their cytoplasm and on the cell membrane. Coculture of peripheral
blood mononuclear cells with Caki-1, K562, HCT116, respectively, resulted in CD56+CD16+ NK cells deletion without af-
fecting CD56+/CD16− NK subset and immature NK cells generated in vitro from CD34+ cells. Natural killer cell apoptosis
seemed to be preferentially triggered by cancer cells because HLA-A0201+ NK cells were only marginally affected by al-
logeneic HLA-A0201− peripheral blood mononuclear cells. Caki-1 cell–mediated NK cell apoptosis was reduced by an
anti–β2-integrin (CD18) monoclonal antibody but was NKG2D-, granule exocytosis–, and caspase-independent.
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Introduction
Advanced renal cell carcinoma (RCC) is a fatal disease with a median
survival of approximately 1 year [1,2]. Nevertheless, RCC is consid-
ered to be a malignancy potentially susceptible to innate and adaptive
immune responses of the host because a small subset of patients with
advanced disease achieves spontaneous or immunotherapy-induced
complete remission [3–5]. The cellular and molecular mechanisms
underlying these complete remissions are not completely understood,
although a variety of inflammatory cells including T and Natural killer
(NK) cells have been identified in RCC lesions [6].
Approximately 90% of RCC lesions express HLA-class I antigens
[7]. According to the missing self hypothesis [8,9], the immunolog-
ical control of RCC is likely to be ascribed to T cells rather than to
NK cells because NK cell’s cytotoxicity is negatively regulated by
HLA-class I expression on malignant cells through its interaction
with killer inhibitory receptors (KIRs) [10]. However, recent find-
ings have underlined that de novo expression of NKG2D ligands
(NKG2DLs) on HLA-class I antigen–positive malignant cells re-
stores sensitivity to NK cell–mediated cytotoxicity despite HLA
matching [11], thus reevaluating the potential role of NK cells in
controlling HLA-class I–positive malignancies [12].
Nonclassic HLA-class I antigen–related molecules MICA and
MICB are major ligands of NKG2D and are often expressed on can-
cer cells. They share 84.3% of amino acids sequence identity and are
highly polymorphic.
The expression of NKG2DLs, MICA/B, and its relationship with
infiltration of the tumor microenvironment by inflammatory cells in
RCC specimens have not clearly been investigated so far. Using a
home-made monoclonal antibody (mAb) recognizing a common epi-
tope of MICA and MICB (MICA/B–specific), WW6B7, we stained
a tissue microarray (TMA) composed of 140 RCC lesions: we pres-
ent evidence that cultured renal cancer cells and clinical RCC speci-
mens express MICA/B. Most interestingly, however, these tumors are
characterized by inflammatory infiltrates poor in NK cells and en-
riched in CD16+ macrophages. Infiltration of RCC lesions by these
cells may have clinical significance because it is associated with ad-
vanced stage of the disease and poor grade of differentiation. Data
from in vitro model developed to address underlying mechanisms
suggest that these finding may reflect NK cell deletion by RCC cells
due to apoptosis involving β2-integrin, CD18–mediated interaction.
Materials and Methods
Cell Lines
The RCC cell line Caki-1, the NK cell–sensitive myeloid cell line
K562, the cervical carcinoma cell line HeLa, the melanoma cell line
D10, and the colorectal carcinoma (CRC) cell line HCT116 were
cultured in OptiMem reduced serum medium (Invitrogen, Carlsbad,
CA) supplemented with 5% FBS.
Antibodies and Reagents
The generation and the specificity of the MICA/B mAb, WW2G8,
have been described elsewhere [11]. The MICA/B mAb WW6B7 was
generated in our laboratory using the methodology of Kohler and
Milstein [13]. The specificity of mAb WW6B7 was determined by
Western blot and flow cytometry analysis of MICA+ and MICA− cell
lines and MICB+ and MICB− transfectants. Allophycocyanin (APC)-
conjugated anti-MICB, phycoerythrin (PE)-conjugated anti-MICA and
anti-NKG2D mAbs were purchased from R&D Systems (Abingdon,
United Kingdom). Biotinylated anti-CD16, biotinylated anti-CD56,
and matching isotype mouse mAbs were purchased from DAKO
(Glostrup, Denmark) and Novocastra (Newcastle, United Kingdom).
Fluorescein isothiocyanate (FITC)–conjugated anti-FcγIII (anti-CD16),
PE-conjugated anti-CD56, peridinin chlorophyl protein–conjugated
anti-CD56, APC-conjugated anti-CD3 mAbs, FITC-conjugated
goat–anti–mouse immunoglobulin G (IgG) F(ab)2 antibodies, and
annexin V–FITC apoptosis detection kit I were purchased from BD
Bioscience (San Jose, CA). Magnetic bead–conjugated anti-CD34
and anti-CD56 mAbs were purchased fromMiltenyi Biotec (Miltenyi
Biotech, Bergisch Gladbach, Germany). Purified anti-CD18 was pur-
chased from BD Bioscience. Interleukin 2 (IL-2) and stem cell factor
(SCF) were purchased from Hoffmann-LaRoche (Basel, Switzerland)
and Peprotech (Rocky Hill, NJ), respectively. Concanamycin A was
purchased from Sigma Chemical, Co. (St. Louis, MO). The general
caspase inhibitor, Z-VAD-FMK, was purchased from BD Bioscience.
Cell Isolation Activation and Expansion
Peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll-Hypaque density gradient separation. Cells were cultured in
RPMI 1640 medium supplemented with 10% fetal calf serum, glu-
tamine (2 mM), and gentamicin, thereafter referred to as complete
medium (CM).
Healthy stem cell donors gave permission for a fraction of their
CD34+ cells to be used for research under institutional review
board–approved National Hearth Lung and Blood Institute (National
Institutes of Health, Bethesda, MD) stem cell allotransplantation
protocols. CD34+ cells were isolated as previously described [11,14],
counted, and frozen in liquid nitrogen until use. CD34+ cells were
then cultured in CM in 96-well U-bottom plates (Costar, Corning,
NY) for 21 days. Cells were stimulated every 5 days with 50 ng/ml
SCF and recombinant IL-2 (200 U/ml). To obtain a purified CD56+
cell population, CD34+ cells cultured in SCF and IL-2 or PBMC
stimulated for 4 days with IL-2 were stained with magnetic bead–
conjugated anti-CD56 mAb (Miltenyi Biotech) and passed through
a magnetic column. In the absence of magnet, a vigorous mechanic
pressure sufficed to elute CD56+ cells retained in the column.
Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted from 3 × 106 cultured cells using a Qiagen
(Basel, Switzerland) RNeasy kit. Complementary DNA (cDNA) first
strand was produced using a SuperScript First-Strand Synthesis Sys-
tem using oligo(dt)12-18 antisense primers (Invitrogen, Lucerne, Swit-
zerland). MICA and MICB transcripts were amplified from cDNA
by 30 cycles of polymerase chain reaction in the presence of the
following primers: MICA/MICB sense primer (5′ACACCCAGCAG-
TGGGGGGAT3′); MICA antisense primer (5′GCAGGGAATTG-
AATCCCAGCT3′); and MICB antisense primer (5′AGCAGTCGT-
GAGTTTGCCCAC-3′) [15]. The amplification conditions consisted
of denaturizing (95°C for 60 seconds), followed by annealing (56°C
for 60 seconds), and extension (72°C for 60 seconds). Amplified frag-
ments were analyzed in 1.5% agarose gel electrophoresis in the pres-
ence of ethidium bromide (Sigma).
Flow Cytometry
Magnetically sorted CD56+ cells were cultured in CM in the pres-
ence of Caki-1 cells for 8 to 12 hours at 37°C in a 5%CO2 atmosphere.
Nonadherent cells were harvested and stained with a PE-conjugated
Neoplasia Vol. 11, No. 7, 2009 NK Cell Infiltration in RCC and CD18 Sconocchia et al. 663
anti-CD56 and with an APC-conjugated anti-CD3 mAbs for 30 min-
utes at 4°C. Cells were washed twice in PBS and stained for 15 minutes
in the dark at room temperature in the presence of FITC–annexin V
and propidium iodide diluted in 0.5 ml of an appropriate buffer. On
the basis of a profound difference between NK cell and Caki-1 cell size
scatter, cells were analyzed after three- to four-color staining by defin-
ing an electronic gate on lymphocytes area using a FACSCalibur
flow cytometer (Becton-Dickinson). For the analysis of the impact of
PBMC on allogeneic NK cells, HLA-A0201− and HLA-A0201+
PBMC from healthy donors were cultured in the presence of IL-2
for 5 days. Cells were then mixed and cultured for 8 to 12 hours, har-
vested and stained with an APC-conjugated anti-HLA-A0201 mAb,
and PE-conjugated anti-CD56 mAb and a PE-Cy5–conjugated anti-
CD16 mAb. Cells were washed and stained with FITC-conjugated
annexin Vas above indicated. Natural killer cells apoptosis was detected
by posting an electronic gate on HLA-A0201+ CD16+ cells. To exclude
CD16+ small monocytes, we analyzed only CD56+annexin V+ cells.
Relative apoptosis units (RAUs) were calculated giving 100 apop-
tosis units to the annexin V + NK cell value obtained in the presence
of cancer cells at PBMC/cancer cell ratio of 4:1. Then, RAUs were
calculated as follows: RAU = % of annexin V + NK cells without
cancer cells/% of annexin V + NK cells with cancer cells × 100.
Proliferation Assays
Peripheral blood (PB) CD56+ cells and immature CD56+ cells were
magnetically sorted and cultured (1.5 × 105/ml) in the presence of
K562 cells at a 2:1 effector/target ratio. After a 3-day culture at 37°C,
CD56+ cells were magnetically sorted and counted. Then, 100-μl
aliquots of cell cultures depleted of CD56+ cells were transferred in
a 96-U/well containing 100 μl of fresh CM and incubated for 2 days
at 37°C in a 5% CO2 atmosphere. Cells were then pulsed with tritiated
thymidine (3H-TdR; 1 μCi/well; Amersham Biosciences, Piscataway,
NJ). After an additional 18-hour incubation at 37°C, 3H-TdR incor-
poration was measured using a beta scintillation counter.
RCC Specimens and TMA
TMAs were constructed using formalin-fixed, paraffin-embedded
tissue blocks from RCC resections representing part of the tissue
specimen collection of the Institute of Pathology, University of Basel
(Basel, Switzerland). Representative regions of each tumor were iden-
tified using hematoxylin and eosin–stained slides from each block.
Tissue cylinders with a diameter of 0.6 mm were punched from
the tumor areas of each block (RCC punches) and transferred into
a recipient paraffin block using a home-made semiautomated tissue
arrayer. MICA/B was detected using mAb WW6B7 and a secondary
biotinylated rabbit–anti–mouse IgG antibody. CD16 and CD56 were
detected by staining with biotinylated anti-CD16 and anti-CD56
mAbs. One hundred forty RCC lesions were evaluated in this study.
To evaluate correlation with tumor grade, 130 RCC lesions were
included in the analysis, whereas 10 RCC lesions were excluded be-
cause no grading information was available. For tumor stage, we in-
vestigated 121 RCC lesions divided as follows: 43 were identified as
primary and 78 were identified as metastatic RCC. Nineteen speci-
mens were excluded from the analysis because no information on stag-
ing was available.
To evaluate CD16+ cell level of infiltration, the absolute number
of infiltrating CD16+ cell was counted in each RCC lesion. For sta-
tistical analysis, the level of CD16+ infiltrating cells was considered low
when 100 cells or less (score 1) per punch were detected and high
when the absolute number of infiltrating CD16+ cells was greater than
100 (score 2).
Statistical Analysis
The significance of statistical differences between the low (score 1)
and high levels (score 2) of CD16+ cell infiltration in relationship
with tumor grade and stage was assessed by using a χ 2 test. Analysis of
NK cell deletion was performed by using Wilcoxon tests and t tests.
Results
Expression of MICA/B in RCC Lesions
Incubation with MICA/B–specific mAb WW6B7 of the TMA
under investigation, including 140 RCC lesions, resulted in the
staining of virtually all (>95%) punches. The staining was generally
of strong intensity (Figure 1A) and localized in the cytoplasm and cell
membranes of cancer cells, whereas it was undetectable in the stromal
cells (Figure 1, B and C ) frequently associated with RCC.
Predominance of CD56−/CD16+ Cells in the RCC
Inflammatory Infiltrate
We analyzed the nature of the inflammatory cells infiltrating RCC
lesions by comparatively evaluating the expression of CD56 and
CD16 in the TMA under investigation. Surprisingly, the CD56+/
CD16+ cell ratio in the RCC microenvironment was generally lower
than 1 (Figure 2A), suggesting that a predominant number of CD16+
cells were CD56−. These CD16+CD56− cells showed a large size and
complex morphology, strongly resembling macrophages (Figure 2B).
Conversely, CD56 expression was predominantly observed on the
cell membranes of cancer cells in approximately 25% of the RCC
specimens analyzed and was only minimally detectable in RCC infil-
trating inflammatory cells (Figure 2A, right, lower panel ). Further
analysis of RCC microenvironment demonstrated the prevailingly
myeloid, CD68+, nature of the inflammatory CD16+ infiltrate (data
not shown). To quantify the discrepancy between the expression of
CD16 and CD56 inflammatory infiltrate, we compared the absolute
number of CD16+ cell infiltration with that of infiltrating CD56+
cells in 108 available RCC lesions. Figure 2C clearly shows that most
of the CD16+ cells were CD56−, and the level of CD56+ cells into
the RCC microenvironment was negligible.
Association of CD16+ Macrophage Infiltration with Cell
Differentiation and Disease Progression in RCC
Clinical features associated with RCC infiltration by CD16+ cells
were then analyzed. A high level, score 2 (Materials and Methods), of
CD16+ cell infiltration was significantly .023 more frequently detect-
able in metastatic than in primary RCC lesions. As shown in Table 1,
a score 2 of CD16+ cell infiltration was only identified in 6 of 43
RCC primary lesions, whereas it was detectable in 25 of 78 metastatic
RCC lesions. In contrast, there was no statistically significant differ-
ence between score 1 of CD16+ cell infiltration of primary and that
of metastatic RCC lesions. Furthermore, high-level, score 2, CD16+
cell infiltration was also significantly (P = .007) associated with poor
differentiation (G3 and G4) of RCC cells, suggesting that high-grade
tumors might shape their microenvironment by recruiting CD16+
myeloid cells.
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Figure 2. Renal cell carcinoma inflammatory infiltrates is mainly composed of CD16+ macrophages. (A) Two serial sections of RCC
lesions (upper and lower panels) taken from the same areas of RCC specimens used for the construction of the indicated TAM. The
punches in the upper panel were stained with a biotinylated anti-CD16 mAb, whereas those in the lower panel were stained with a
biotinylated anti-CD56 mAb. Upper and lower right panels represent an enlargement of the indicated punches. Panel-positive cells
are stained in brown. In either case, original magnifications of ×20 are reported. (B) Detailed morphology of CD16+ cells identified
in the indicated RCC area (original magnification, ×60). A, right panel: Horizontal arrow indicates CD16+ interstitial cells, whereas ver-
tical arrow indicates CD56+ RCC cells. (C) Absolute number of low levels of CD16+ cell infiltrate (≤50) and their relative CD56+ infiltrate,
n = 48; intermediate levels of CD16+ cell infiltration and their relative CD56+ cell infiltration, n = 32; and high levels of CD16+ cell
infiltration and their relative CD56+ cell infiltration, n = 28. Asterisks indicate CD56+ cell infiltrate.
Figure 1.MICA/B expression in RCC TMA. (A) Punches shown in this panel are derived from a randomly selected area of a slide contain-
ing 140 RCC lesions stained with WW6B7 mAb. The TMA methodology and WW6B7 mAb staining are described in the Materials and
Methods section. Positive cells are stained in brown. (B) An enlargement (×20) of the indicated punches. (C) Detail of an RCC punch
containing tumor cells, stroma, and inflammatory infiltrates at an original magnification of ×40. Horizontal arrows indicate interstitial
cells, whereas vertical arrows indicate RCC cells.
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Expression and Distribution of MICA and MICB by Human
RCC Cell Line, Caki-1
The defective NK cell infiltration in RCC lesions with highMICA/B
NKG2DL expression prompted us to investigate the underlying mech-
anism(s) using an in vitro model.
First, we analyzed MICA and MICB gene and protein expressions
in the RCC cell line, Caki-1, by reverse transcription–polymerase
chain reaction and flow cytometry analysis. Caki-1 cells clearly ex-
press MICA and MICB genes (Figure 3A). Interestingly, however,
surface expression of MICB protein on Caki-1 cells was relatively
low, whereas MICA was undetectable. In contrast, HeLa cells were
MICA highly positive but MICB-negative, whereas K562 were
MICA-negative but MICB-positive (Figure 3B).
To investigate the intracellular NKG2DL expression, permeabilized
Caki-1 cells were incubated with anti-MICA–specific mAb WW2G8
or with anti-MICA/B mAb WW6B7. As shown in Figure 3C , mAb
WW2G8 did not stain Caki-1 cells but stained HeLa cells, indicat-
ing that MICA was neither on the surface nor intracellular. MICA/
B–specific WW6B7 mAb stained Caki-1, D10, and HeLa cells. Most
interesting, the staining intensity of permeabilized Caki-1 cells was
higher than that of nonpermeabilized cells (Figure 3D). In contrast,
the staining patterns of nonpermeabilized and permeabilized HeLa
cells were similar. These results suggest that the MICB molecule is
partially retained in Caki-1 cell cytoplasm and partially transported
to cell surface. These results matched immunohistochemistry data
showing NKG2DL expressed in the cytoplasm and on the cell surface
of RCC cells.
CD56+ Cell and Caki-1 Cell Interaction Results in
Mutual Deletion
To investigate whether the defective NK cell infiltration in RCC
lesions reflected a deletion of NK cells upon interaction with RCC
Table 1. Association of the Level of CD16+ Cell Infiltration with Disease Progression and Cancer
Cell Differentiation in RCC.
CD16+ Cells Score 1 Score 2 P
RCC stage
Primary RCC 37 (86%) 6 (14.0%)
Metastatic RCC 53 (68%) 25 (32.0%) .023*
RCC grade
G1 + G2 35 (87.5%) 5 (12.5%)
G3 + G4 59 (65.5%) 31 (34.4%) .0070*
G indicates RCC grade of differentiation.
*Statistically significant P value.
Figure 3.MICA and MICB gene and protein expressions in Caki-1 cells. (A) MICA (442 bp) and MICB (677 bp) transcripts were amplified
by polymerase chain reaction from Caki-1 cDNA by using a single MICA/B sense primer and two MICA- or MICB-specific antisense
primers as indicated in the Materials and Methods section. (B) The indicated tumor cell lines were stained either with a commercial
APC-conjugated anti-MICB (left panel, gray areas) or with a commercial PE-conjugated anti-MICA (right panel, gray areas). The black
areas show the intensity of fluorescence upon staining with APC- or PE-conjugated matching isotype mAbs. (C) The indicated tumor
cell lines (1 × 106) were permeabilized and incubated with WW6B7 mAb (solid lines) or WW2G8 mAb (dashed lines) or an isotype-
matched IgG1 mAbs (solid thick lines). After a 30-minute incubation in ice, cells were washed, and FITC-conjugated goat anti–mouse
F(ab)2 were added to the cell pellet. Cells were then analyzed by flow cytometry. (D) Nonpermeabilized (dashed lines) or permeabilized
(solid lines) cells (1 × 106) were incubated with WW6B7 mAb and stained with a FITC-conjugated goat anti–mouse F(ab)2 antibodies.
The overlapping solid thick lines show the fluorescence given by control isotype IgG1 mAbs in nonpermeabilized or in permeabilized
tumor cells.
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cells, resting or IL-2–activated PBMCs were cultured in the presence
or absence of Caki-1 cells. After 8 hours of incubation at 37°C, per-
centages of apoptotic and/or necrotic CD56+ cells were evaluated by
flow cytometry using annexin V and propidium iodide staining, re-
spectively. To control the effect of the cell density on CD56+ cells,
the total number of CD56+ cells cultured in the absence of Caki-1
cells was equal to that of the mix of CD56+ and Caki-1 cells cultured
in each experiment. Data from a representative experiment shown in
Figure 4A indicated that unstimulated CD56+ cells included approx-
imately 7.5% of apoptotic cells and 27% of cells in transition from
apoptosis to necrosis. In contrast, in the presence of Caki-1 cells, the
percentage of apoptotic CD56+ cells rose up to 16%, whereas that of
the cells in transition rose up to 57%. In the presence of IL-2 and in
the absence of Caki-1 cells, the percentage of damaged CD56+ cells
was reduced to 9.4%, whereas percentages of apoptotic or apoptotic/
necrotic cells in the presence of Caki-1 RCC cells were similar (22%
and 41%, respectively) to those observed in resting CD56+ cells. To
evaluate the specificity of Caki-1–induced NK cell apoptosis, we sep-
arately cultured–IL-2 activated PBMCs obtained from HLA-A0201+
donors with IL-2–stimulated PBMCs obtained from three distinct
HLA-A0201− healthy donors, Caki-1 cells, and HCT116 CRC cell
line. To prevent IL-2–stimulated NK cell killing machinery upon
conjugation with IL-2–stimulated allogeneic PBMCs, cells were cul-
tured in CM supplemented with a high-dose concentration of con-
canamycin A (0.3 μM). Figure 5 shows that Caki-1 and HCT116
clearly induced NK cell apoptosis, whereas IL-2–activated HLA-
A0201-negative PBMCs did not, suggesting that NK cells were pref-
erentially affected by RCC and CRC cell lines in the presence of an
inhibitor of NK cell killing machinery.
RCC Caki-1 Cells Preferentially Eliminate CD56+CD16+
Cell Subset
We then asked which NK cell subset is affected by the interaction
with RCC Caki-1 cells. Peripheral blood mononuclear cells were cul-
tured for 3 to 4 days at 37°C in CM in the presence of IL-2. Cells
were then incubated overnight in the presence or absence of Caki-1
cells. Nonadherent cells were harvested and stained with a FITC-
conjugated anti-CD16 or a PE-conjugated anti-CD56 mAb. Table 2
shows that, in the presence of Caki-1 cells, percentages of CD56+
CD16+ cells but not CD56+CD16− cells in PBMC from five of
Figure 4. Caki-1 cells induce CD56+ cells elimination upon effectors/target cell interaction. (A) Peripheral blood mononuclear cells were
cultured in the presence or absence of 500 U of IL-2. After a 4-day culture at 37°C, cells were harvested and subjected to a Ficoll/
Hypaque gradient separation. Cells were then cultured in the presence or absence of Caki-1 cells at a 5:1 effector/target ratio at 37°C
in a 5% CO2 incubator. After 8 hours, nonadherent cells were harvested and stained as indicated in the Materials and Methods section.
Peripheral blood mononuclear cells were analyzed by flow cytometry as indicated by defining an electronic gate on CD56+ cells. This figure
shows one of three experiments performed with similar results. (B) Peripheral blood mononuclear cells were cultured for 4 days in the
presence of IL-2 (500 U/ml), whereas immature CD56+ cells were obtained from G-CSF–mobilized PB CD34+ cells cultured in the presence
of IL-2 and SCF for 21 days. Peripheral blood–CD56+ cells and immature CD56+ cells were magnetically sorted and cultured (1.5 × 105) in
the presence of K562 cells at a 2:1 effector/target ratio. After a 3-day culture, CD56+ cells were magnetically sorted and counted (upper
panel). Subsequently, aliquots of the same cell cultures depleted of CD56+ cells were transferred in a 96-U/well and left to proliferate for
2 days. Proliferation was then measured by 3H-thymidine incorporation (lower panel). This figure shows one of three experiments per-
formed with similar results.
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six healthy individuals were significantly reduced compared with
PBMCs cultured in the absence of Caki-1 cells (P = .02), suggesting
that Caki-1 cells eliminated cytotoxic NK cells without affecting reg-
ulatory CD56+CD16− NK cells.
Preferential Elimination of Terminally Differentiated NK
Cells upon Interaction with Target Cells
Similar results were obtained when we cultured magnetically
sorted PB CD56+ cells with the NK cell–sensitive cell line, K562.
After a 3-day culture at 37°C, viable PB-CD56+ cells were separated
from K562 cells by magnetic sorting. Figure 4B shows that noncytotoxic,
immature, CD56+CD16− cells (generated from granulocyte colony-
stimulating factor mobilized CD34+ cells) [14] were clearly recovered,
whereas PB-derived CD56+ cells were not (Figure 4B, upper panel ) sug-
gesting that IL-2–activated PB-CD56+ cells were eliminated upon inter-
action with target cells. To determine whether sorted PB-CD56+ and
immature NK cells affected K562 proliferation, aliquots of K562 cell cul-
tures depleted of PB-CD56+ or immature NK cells (shown in Figure 4B,
lower panel ) were further cultured as indicated in theMaterials andMeth-
ods section. After a 3-day incubation, we observed K562 cell proliferation
after culture in the presence of immature NK cells. In contrast, there was
no K562 proliferation after culture in the presence of PB-CD56+ cells
(Figure 4B, lower panel ).
Caki-1–Dependent NK Cell Apoptosis Involves CD18
Caki-1 cell–dependent NK cell elimination did not require
NKG2D blockade and granule exocytosis because addition of a
blocking anti-NKG2D mAb or concanamycin A did not improve
NK cell recovery (data not shown). Furthermore, Table 3 shows that
the elimination of NK cells by FAS ligand–negative Caki-1 cells (data
not shown) was also unaffected by the addition of optimal concen-
trations of the general caspase inhibitor, Z-VAD-FMK, to the cul-
tures, suggesting that the NK cell elimination by Caki-1 cells was
caspase- and FAS-independent. Using an anti-CD18 mAb, however,
Caki-1–dependent NK cell apoptosis was significantly reduced. In
contrast, as expected, CD56+CD16− cells were 8.1 ± 3.3% of the
total NK cells and they were not negatively affected neither by
Caki-1 cells (27 ± 8.4%) nor by HCT116 cells (16.3 ± 0.4%). Fig-
ure 6, upper panel, shows a dose-response experiment showing the
effect of such mAb on CD56+CD16+ cells of healthy donors after
12 hours of incubation with intercellular adhesion molecule 1
(ICAM-1+) Caki-1 cells. To further investigate whether this observa-
tion was restricted to Caki-1 cells, we included in the outlined exper-
iment a MICA/B+, ICAM-1− CRC cell line, HCT116. Conversely,
Figure 6, lower panel, shows that HCT116 cells triggered NK cell apop-
tosis, which was significantly reducedwhenNK cells andHCT116were
cultured in the presence of logarithmic concentration doses of anti-
CD18, suggesting that Caki-1– and HCT116-dependent NK cell
apoptosis may depend on NK–cancer cell conjugation that could at
least involve CD18 on NK cells and ICAM-1 on cancer cells. Notably,
NK cell apoptosis inhibition was never complete, suggesting that mole-
cules other than CD18 may also be involved.
Discussion
Renal cell carcinoma is considered an immunogenic tumor because
spontaneous regressions and long-lasting complete remissions in a small
subset of patients undergoing adoptive lymphokine-activated killer cell
Figure 5. Natural killer cell apoptosis is preferentially induced by
cancer cells. Peripheral blood mononuclear cells of an HLA-A0201+
healthy donor and PBMCsof threeHLA-A0201− healthy donorswere
cultured in the presence of IL-2 (200 U/ml) for 5 days. HLA-A0201+
PBMCswere thenharvested andcultured in the absenceor presence
of IL-2–stimulated HLA-A0201− PBMCs from donors 1, 2, and 3, re-
spectively. Caki-1 and HCT116 cells were used as positive controls.
This figure shows cumulative data regarding the effects of PBMCs of
the indicatedHLA-A0201− donors onHLA-A0201+NKcells, whereas
Caki-1 and HCT116 representing the effects of Caki-1 and HCT116
on HLA-A0201–positive and –negative cells are also reported. All of
the cell culture conditions which included NK cells in the absence or
presence of allogeneic PBMC or in the presence of cancer cell lines
were supplemented with concanamycin A (0.3 μM).
Table 2. Caki-1 Cells Induce Elimination of CD56+CD16+ Cell Subset without Affecting CD56+
CD16− NK Cells*.
Caki-1 Cells
− − + +
CD56+CD16+ (%) CD56+CD16− (%) CD56+CD16+ (%) CD56+CD16− (%)
Case
1 14 9.4 5.83 12.6
2 7.9 7.6 7.6 8.4
3 12.5 10.8 0.9 7.7
4 9.4 8.5 2.3 10.2
5 4.8 8.4 0.9 10
6 1.4 7.9 0.0 2.8
Mean ± SD 8.3 ± 4.7 8.7 ± 1.1 2.8 ± 2.8† 8.6 ± 3.3
*Peripheral blood mononuclear cells were cultured in the presence of IL-2 as detailed in the Ma-
terials and Methods section before culture in the presence or absence of Caki-1 RCC cells.
†t test: CD16+ versus CD16+/Caki-1, P = .02; CD16+/Caki-1 versus CD16−/Caki-1, P = .007;
bolded numbers, statistically significant differences.
Table 3. Caki-1 Cells Induced Elimination of CD56+CD16+ Cell Subset Is Caspase-Independent*.
Experiments Caki-1 Cells
− − + +
− Z-VAD (40 μM) − Z-VAD (40 μM)
1 12.5 8.0 0.91 1.08
2 5.0 3.91 0.95 0.93
3 9.4 9.28 2.32 3.05
Mean ± SD† 8.96 ± 3.7 7.0 ± 2.8 1.39 ± 0.8 1.68 ± 1.1
*Peripheral blood mononuclear cells were cultured in the presence of IL-2 with or without Z-
VAD-FMK as detailed in the Materials and Methods section before culture in the presence or
absence of Caki-1 RCC cells.
†t test: CD56+CD16+ cells versus CD56+CD16+ cells + Z-VAD-FMK, P = .52; CD56+CD16+ cells +
Caki-1 cells versus CD56+CD16+ cells + Caki-1 cells + Z-VAD-FMK, P = .740; CD56+CD16+ cells
versus CD56+CD16+ cells + Caki-1 cells, P = .02; CD56+CD16+ cells versus CD56+CD16+ cells
versus CD56+CD16+ cells + Caki-1 cells + Z-VAD-FMK, P = .03.
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cell and/or IL-2 immunotherapy have been observed [3]. Why such
response occurs is unknown. Signs of local immune activation have
been described including the presence of cellular infiltrates composed
of CD4+ and CD8+ T cells and dendritic cells [8]. Interestingly,
after enzymatic digestion of RCC lesions, Schleypen et al. [6] have iso-
lated two populations of NK cells. One was CD56bright CD16negative
and did not lyse K562 cells, whereas the other one was CD56low
CD16positive and acquired an efficient cytotoxic activity to K562 cells
upon IL-2 activation. The ineffectiveness of the first NK cell subset
may be due to its harboring a population of myeloid cells because a
subset of CD56-positive monocyte/macrophage with antiproliferative
activity on tumor cell lines [14,16,17] has been described recently.
Natural killer cell cytotoxicity is regulated by a balanced activation
of KIRs and natural cytotoxic receptors. Killer inhibitory receptors
bind HLA-class I molecules delivering an inhibitory signal upon re-
cruitment of tyrosine phosphates [18]. NKG2D is a major NK cell–
activating receptor that binds stress-induced nonclassic HLA-class I
molecules MICA, MICB, and UL16-binding proteins [19,20].
According to the missing self hypothesis, host NK cells may kill
autologous cancer cells only when malignant cells do not express
HLA-class I antigens. Although loss of HLA-class I expression has
been described in a variety of solid tumors [21], myeloid leukemia
cells express high levels of HLA-class I antigens. However, they can
still be killed by HLA-matched class I NK cells, suggesting that
HLA-class I expression per se is not sufficient to prevent NK cell
cytotoxicity [11].
Currently, there are enough data suggesting that de novo expression
of NKG2DL on HLA-matched cancer cells overrides the inhibitory
activity of KIRs leading to cancer cell elimination [11,22,23].
The relationship occurring among NK cells, RCC cells, and RCC
tumor microenvironment is poorly characterized. Taking advantage
of the availability of a RCC TMA, we assessed NKG2DL expression
in RCC lesions obtained from 140 patients with RCC. We clearly
demonstrated that RCC cells expressed high levels of cytoplasmic
and cell surface MICA/B in more than 95% of the TMA punches
analyzed. Notably, we could not find any correlation between the
expression of MICA/B and RCC clinical stages. To address mecha-
nisms underlying defective NK cell infiltration of RCC, we evaluated
the distribution of MICA and MICB in RCC cells analyzing their
gene and protein expressions.
The finding that despite MICA gene expression, only a low level
of MICB antigen is correctly expressed on RCC cell, is intriguing.
Our data suggest that MICA is transcribed but not translated,
whereas a fraction of MICB may be retained into the cytoplasm of
Caki-1 cells. As a result, there may be a suboptimal level of expres-
sion of NKG2DLs on the cell surface of RCC cells.
Although we were not able to determine whether RCC lesions ex-
pressed MICA or MICB, it is likely to hypothesize that they express
MICB because 1) we could detect MICB in RCC Caki-1 cells both
intracellularly and on cell surfaces, but we could not detect MICA
protein, despite MICA gene expression; 2) the location of MICA/B
in TMA cancer cells resembled that observed in Caki-1 cells; and 3)
according to Groh et al. [24], two of two RCC lesions were stained by
a MICA/B–specific mAb, but none of them was stained by a MICA-
specific mAb. Clearly, this conclusion will be strengthened by results
obtained by staining RCC TMA with an MICB-specific mAb.
The expression of MICA/B in most RCC cells might expose them
to NK cell recognition through NKG2D. Therefore, we investigated
infiltration by NK cells in the tumor milieu. We considered NK as
those cells coexpressing CD56 and CD16 markers. Surprisingly, we
found very low levels of NK cell infiltration in RCC, whereas inflam-
matory interstitial cells were mainly CD16+CD56−.
Morphologic and phenotypic analysis of CD16+CD56− cells has
demonstrated that these cells resemble monocyte/macrophage cell
types. This observation was confirmed by the expression of CD68
in the TMA specimens.
CD16+CD68+CD56− myeloid cells are a small subset representing
less than 10% of PB monocytes [25,26]. They expand in different
conditions including sepsis and human immunodeficiency virus in-
fection [27,28]. Interestingly, CD16+ PB monocytes promptly ex-
pand in a variety of malignancies to become approximately 40%
of the total monocyte population. Furthermore, such expansion
becomes even higher, reaching 80% of the total population, when
patients are treated with recombinant human macrophage colony-
stimulating factor [29]. In the early 1990s, van Ravenswaay Claasen
et al. [30] showed that there was an infiltration of CD16+ macro-
phages in RCC, melanoma, and CRC lesions, and they hypothesized
a role of these cells in antitumor cytotoxicity. We also identified
a strong CD16+ macrophage infiltration in most of our clinically
and pathologically well-documented collection of 140 RCC lesions.
However, importantly, our statistical analysis has shown that CD16+
macrophage infiltration is associated with RCC metastasis. In addi-
tion, there was a trend toward an association with poorly differenti-
ated RCC cells.
The role of CD16+ macrophages in RCC milieu is unclear. CD16+
monocytes are reported to be functionally different from the pre-
dominant population of CD14+ monocytes. Consistent with their
ability to be strong producers of tumor necrosis factor α [31], minimal
Figure 6. Natural killer cell apoptosis upon NK/cancer cell interac-
tion involves CD18. After 4 days of incubation with IL-2, PBMCs
were cultured in the presence of Caki-1 cells (upper panel) or
HCT116 (lower panel) with or without logarithmic concentration
doses (μg/ml) of an anti-CD18 mAb at 4:1 ratio, respectively. After
12 hours of culture, nonadherent cells were harvested and stained
as indicated in the Materials and Methods section. Apoptotic
CD56+CD16+ cells were identified as CD56+CD16+annexin V+
cells by analyzing the percentage of green fluorescent cells falling
within an electronic gate surrounding CD56+CD16+ cells. This fig-
ure summarizes the results obtained from three different donors.
Asterisks indicated statistically significant differences (P ≤ .05).
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producers of IL-10 [26,31], and proliferative inhibitors [16,17], they
are considered powerful inflammatory cells. It is possible that CD16+
monocytes play a role in regulating tumor immunosurveillance be-
cause their frequency is strongly increased at a systemic level in a va-
riety of advanced malignancies [29,32,33]. To date, the reasons why
CD16+ monocytes specifically expand in the PB of patients with ma-
lignancies are unknown. One possibility is that advanced solid tumors
may release factors causing CD16+ monocyte expansion [29] or che-
moattracting them on tumor sites [34,35].
Conversely, our in vitro data strongly suggest that CD16+ NK cells
undergo apoptosis upon interaction with target cells, including RCC,
Caki-1, myeloid leukemia, K562 and CRC, HCT116-derived cell
lines, thereby providing a mechanistic explanation to the relative ab-
sence of these lymphocytes from the RCC microenvironment.
We attempted to explore molecular mechanisms by which cancer
cell lines induced RCC apoptosis. We hypothesized an involvement
of a caspase-dependent mechanism or/and a granule exocytosis-
dependent mechanism eventually due to a “friendly fire” situation
triggered by NK cell upon conjugation with cancer cells and after
granule exocytosis. Therefore, we used Z-VAD, a potent general cas-
pase inhibitor, and concanamycin A, a specific inhibitor of a granule-
dependent cytotoxicity. Both inhibitors failed to prevent NK cell
elimination by Caki-1, FAS ligand–negative and HCT116, FAS
ligand–positive cells suggesting that this phenomenon is caspase-,
perforin-, and FAS-independent and also excluding that the possibil-
ity of perforin spilling in the intercellular area of effector/target cell
surface may cause autologous NK damage.
Natural killer cells could be also damaged directly and/or indirectly
by myeloid cells resident in the tumor microenvironment. Resident
myeloid cells could impair the function of the host’s NK cells through
an alteration of the metabolism of L-tryptophan, L-arginine, and
arachidonic acid and by producing nitric oxide [36,37]. In our expe-
rience, the Caki-1–dependent elimination of NK cells was not affected
by the depletion of monocytes from cell cultures used for in vitro ex-
periments (Sconocchia et al., unpublished data). Obviously, to make
any clear conclusions, further studies are required.
CD18 is a cell surface receptor composed of a constant chain that
is associated with a distinct α chain to characterize four distinct cell
surface molecules including CD11a (LFA-1), CD11b (MAC-1),
CD11c, and CD11d. CD18 is expressed on NK cells mainly as
LFA-1 and MAC-1. CD18 is also involved in NK cytotoxicity and
cell adhesion because LFA-1 contributes to NK cytotoxicity. Anti-
CD18 was able to reduce partially the annexin V expression on
cytotoxic NK cells upon conjugation with cancer cells. Thus, it is
possible to assume that, in normal conditions, different levels of
β2-integrin ligands on the cell surface of cancer cells may regulate
the extent of NK cell apoptosis.
Recently, it has been shown that neutrophil β2-integrins regulate
neutrophil apoptosis through the activation of nuclear factor κ light
chain enhancer of activated B cells and mitogen-activated protein
kinase–extracellular signal–regulated kinase [38]. Thus, we hypothesize
that CD18 ligation of LFA-1 and MAC-1 on NK cells could affect
NK cells’ survival upon cancer cell interaction. Our data suggest that
the disruption of the interaction between CD18 on NK cells and
ICAM-1 on Caki-1 cells partially prevents Caki-1 cell–dependent
apoptosis. In contrast, it is not clear how NK cell’s CD18 is affecting
HCT116-dependent NK cell apoptosis because our HCT116 cells
are ICAM-1–negative. One possible explanation could reside on the
fact that CD18 interacts with different CD18 ligands including
ICAM-2, ICAM-3, and ICAM-4, which could be expressed on
HCT116, CRC cells.
Finally, our data suggest that other than CD18, additional mole-
cules could be involved in regulating NK cell survival upon conjuga-
tion with target cells including CD16. Infect, ligation of CD16 on
NK cells caused loss of cell surface CD16 expression [39]. However,
it is not completely understood whether the effect is a result of CD16
internalization or NK cells’ elimination.
The identification of strategies possibly improving cytostatic and
antigen-presenting functions of CD16+ myeloid cells and delaying
NK cell apoptosis in the presence of cancer cells may help restore
an efficient immune response in RCC patients.
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